Alogliptin: A new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties

Endocrine Research

Volumn 40, Issue 2, 2015, Pages 88-96

  Kutoh, Eiji ^a,b   Kaneoka, Noriko ^a   Hirate, Mitsuru ^a  

^a Biomedical Center   (Japan)

^b Gyoda General Hospital   (Japan)

Author keywords

Alogliptin; Atherogenic lipids; DPP 4 inhibitors

Indexed keywords

ALOGLIPTIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LIPID; PIPERIDINE DERIVATIVE; URACIL;

ABSENCE OF SIDE EFFECTS; ADULT; ANTI ATHEROGENIC PROPERTY; ARTICLE; BODY MASS; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; WEIGHT GAIN; AGED; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS ISLET BETA CELL; PHYSIOLOGY;

ADULT; AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIPIDS; MALE; MIDDLE AGED; PIPERIDINES; URACIL;

EID: 84929379272     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2014.952743     Document Type: Article

References (31)

1. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-69
2. Harada N, Inagaki N. Incretin and incretin-based therapies. Nihon Rinsho 2010;68:931-42
3. Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol (Oxf) 2012;77:489-99
4. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes and inadequate glycemic control. Diabetes Care 2008;31:2315-17
5. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051-72
6. Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord 2013;13:9
7. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29:14-25
8. Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial. Endocrine 2012;41:435-41
9. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebocontrolled study. Diabetologia 2012;55:915-25
10. Noda Y, Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol 2012;12:8
11. Ta NN, Schuyler CA, Li Y, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011;58:157-66
12. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidylpeptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124:2338-49
13. Kutoh E. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone. Postgrad Med 2011;123:45-52
14. Kutoh E, Ukai Y. Differential regulation of metabolic parameters between super-responders and non-responders treated with sitagliptin. American Diabetes Association (ADA), 73rd Scientific sessions, 1064 p
15. Tominaga M. Diagnostic criteria for diabetes mellitus. Rinsho Byori 1999;47:901-8
16. Ma Y, Olendzki BC, Merriam PA, et al. A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 Diabetes. Nutrition 2008;24:45-56
17. Tominaga M, Makino H, Yoshino G, et al. Japanese standard reference material JDS Lot 2 for haemoglobin A1c. II: Present state of standardization of haemoglobin A1c in Japan using the new reference material in routine clinical assays. Ann Clin Biochem 2005;42:47-50
18. Virani SS, Catellier DJ, Pompeii LA, et al. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis 2011;219:596-602
19. Negi SI, Steinberg L, Polsani VR, et al. Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. J Clin Lipidol 2012;6:50-7
20. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
21. Kutoh E, Hori T. Effect of sitagliptin in type 1 or type 2 diabetic patients with absolute insulin deficiency: a 48 weeks observational study. Br J Med Med Res 2013;3:1910-17
22. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013;15:906-14
23. Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab 2014;16:613-21
24. Kutoh E, Hirate M, Ikeno Y. Distinct effects on metabolic parameters in good responders treated with sitagliptin and alogliptin. American Diabetes Association, 74th scientific sessions, 1042 p
25. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
26. Kutoh E, Hirate M, Ikeno Y. Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes. J Clin Med Res 2014;6:287-94
27. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009;49:S16-29
28. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
29. Ahrén B, Hughes TE. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon- like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrinreleasing peptide in mice. Endocrinology 2005;146:2055-59
30. Creutzfeldt W. The incretin concept today. Diabetologia 1979;16: 75-85
31. Ugleholdt R. Glucose-dependent insulinotropic polypeptide (GIP): from prohormone to actions in endocrine pancreas and adipose tissue. Dan Med Bull 2011;58:B4368